Mystified by MAT? Navigating the Changing Regulatory Landscape Around Medication-Assisted Treatment
Watch the Video on YouTube or Here:
Francesca R. Ozinal – Associate, Epstein Becker Green
Andrew Martin – Chief Operating Officer,
Behavioral Health Association of Providers
There is a confluence of national and local public policy developments regarding mental health, substance use disorders, and treatment. The federal government, working in partnership with states, addresses behavioral health issues and establishes and enforces minimum standards. States, however, have significant power in making decisions—mental health regulations and available services can look very different from state to state, and even from county to county.
Please join the Behavioral Health Association of Providers, Epstein Becker Green, and Nelson Hardiman for a fall webinar series that will address topics highlighting the accelerating legal and policy issues for the behavioral health industry.
Topics for the November 1 session:
Despite reports identifying medication-assisted treatment (MAT) as a critical element of evidence-based treatment, confusion concerning who may dispense, associated compliance requirements, and the relationship between MAT provision and behavioral health providers continues to impede access to MAT.
This webinar will review key licensing and operational issues concerning the various types of MAT, including buprenorphine, naltrexone, and methadone, as well as misperceptions and key compliance issues in instituting MAT.
Have questions? Please contact the presenters or David Stone at [email protected].